Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ivonescimab + docetaxel
- Development stage
- Unknown
- Lead developer
- Akeso
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
Ivonescimab + docetaxel is a combination therapy consisting of **ivonescimab**, a first-in-class humanized IgG1 bispecific antibody that targets both programmed cell death protein 1 (PD-1) and vascular endothelial growth factor (VEGF), and **docetaxel**, a microtubule inhibitor. Ivonescimab inhibits PD-1-mediated immunosuppression and blocks tumor angiogenesis by targeting VEGF, thereby promoting anti-tumor immune activity and reducing tumor vascularization. Docetaxel interferes with microtubule function during cell division, leading to cancer cell death. This combination is under investigation for the treatment of advanced non-small cell lung cancer (NSCLC) that has progressed after PD-(L)1 inhibitor-based therapy, and has received Breakthrough Therapy Designation in China for immunotherapy-resistant NSCLC[2][3][4][5][7].
- Brand names
- TaxotereDocefrezBeizrayDocivyxACT DOCEtaxelTaro-DOCEtaxel
- Other names
- Ivonescimab
02
Targets
TUBB (Tubulin (alpha and beta subunits))PDCD1 (Programmed cell death protein 1 receptor)VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on ivonescimab + docetaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ivonescimab + docetaxel.